Healthcare | May 19, 2026
Zydus Wellness FY26 revenue climbs to Rs. 39.4 billion
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
Initiative focuses on early diagnosis, gut health awareness and long-term gluten-free care for children with celiac disease
Subscribe To Our Newsletter & Stay Updated
